These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172 [TBL] [Abstract][Full Text] [Related]
4. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910 [TBL] [Abstract][Full Text] [Related]
5. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Pyon EY Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461 [TBL] [Abstract][Full Text] [Related]
6. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. Reginster JY Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890 [TBL] [Abstract][Full Text] [Related]
7. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Miller PD Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811 [TBL] [Abstract][Full Text] [Related]
8. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Schimmer RC; Bauss F Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110 [TBL] [Abstract][Full Text] [Related]
9. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558 [TBL] [Abstract][Full Text] [Related]
12. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Rossini M; Viapiana O; Gatti D; Adami S Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399 [TBL] [Abstract][Full Text] [Related]
13. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Reginster JY Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506 [TBL] [Abstract][Full Text] [Related]
14. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. Miller PD; Ward P; Pfister T; Leigh C; Body JJ Clin Exp Rheumatol; 2008; 26(6):1125-33. PubMed ID: 19210886 [TBL] [Abstract][Full Text] [Related]
15. Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy. Amling M; Kurth A Womens Health (Lond); 2009 Sep; 5(5):467-73. PubMed ID: 19702445 [TBL] [Abstract][Full Text] [Related]
16. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614 [TBL] [Abstract][Full Text] [Related]
17. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Frampton JE; Perry CM Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707 [TBL] [Abstract][Full Text] [Related]